AKT-IN-24

KT-IN-24 (Compound M17) is a AKT allosteric inhibitor with anti-tumor activity. KT-IN-24 can target the AKT/mTOR and MEK/ERK signaling pathways and inhibit epithelial-mesenchymal transition, which has a synergistic suppressive effect on TNBC, promoting cell apoptosis while inhibiting proliferation and migration when used in combination with Trametinib (HY-10999) [1].

Product Specifications

UNSPSC

12352005

Target

Akt; Apoptosis; ERK; MEK; mTOR

Related Pathways

Apoptosis; MAPK/ERK Pathway; PI3K/Akt/mTOR; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Smiles

O=[N+](C1=C(C=CC=C1)OCC(NC2=CC=CC(CC(O[C@H](C/C=C(C)\C)C3=CC(C4=C(O)C=CC(O)=C4C3=O)=O)=O)=C2)=O)[O-]

Molecular Formula

C32H28N2O10

Molecular Weight

600.57

References & Citations

[1]Hongwei Han, et al. Trametinib and M17, a novel small molecule inhibitor of AKT, display a synergistic antitumor effect in triple negative breast cancer cells through the AKT/mTOR and MEK/ERK pathways. Bioorg Chem. 2024 Nov 22:154:107981.